Companies to develop new tumour marker:
This article was originally published in Clinica
Executive Summary
Canada's York Medical and its partner Centre for Molecular Immunology (CIM) are to develop a monoclonal antibody for diagnosing cancers of epithelial origin, such as those in the head, neck, breast and lung. The product, DiaCIM, will use the human version of the monoclonal antibody hR3 to identify cancers that over-express epidermal growth factor receptor (EGF-r), which is associated with the continuing growth of cancer cells, metastatic spread and poor prognosis. DiaCIM could also help identify patients who may respond to therapeutic versions of hR3, said Mississauga, Ontario-based York Medical.